Sonoma Pharmaceuticals (STU:O8Z3) 3-Year EPS without NRI Growth Rate : 28.70% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Sonoma Pharmaceuticals 3-Year EPS without NRI Growth Rate?

Sonoma Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2023 was €-0.07.

During the past 3 years, the average EPS without NRI Growth Rate was 28.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 44.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 30.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Sonoma Pharmaceuticals was 56.40% per year. The lowest was -370.90% per year. And the median was 28.70% per year.

Competitive Comparison of Sonoma Pharmaceuticals's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sonoma Pharmaceuticals's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Sonoma Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.

Sonoma Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Sonoma Pharmaceuticals (STU:O8Z3) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Sonoma Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sonoma Pharmaceuticals (STU:O8Z3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (STU:O8Z3) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

SNOA:USA

Address

5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301

Website

https://www.sonomapharma.com

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, and other countries.

Sonoma Pharmaceuticals (STU:O8Z3) Headlines

No Headlines